At the basic research level, in vitro cell models such as IL-4/IL-13-stimulated keratinocytes (KCs) (50) will assess PRP’s direct barrier repair capacity via growth factors, while in vivo animal models like chronic eczema mouse models (51) will visually demonstrate its overall improvement of eczema phenotypes, including pruritus, erythema, and desquamation. This evidence concerns the gene IL13 and Eczematoid dermatitis.